Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

2.3K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.3K
Odds Ratio01:09

Odds Ratio

2.0K
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
2.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

510
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
510
Hazard Ratio01:12

Hazard Ratio

664
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
664
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

484
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
484
Hazard Rate01:11

Hazard Rate

467
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex Differences in 6-Year Change in eGFR and ACR in a Multiethnic Population: The HELIUS Study.

Kidney medicine·2026
Same author

Vascular Access Surgery Timing: A Prospective European Cohort Study in Elderly Patients with ESKD.

Kidney360·2026
Same author

Demographics, longitudinal changes and outcome of high blood pressure in children and adolescents on kidney replacement therapy: 15 years of data from the ESPN/ERA Registry.

Pediatric nephrology (Berlin, Germany)·2026
Same author

The evolution of symptom burden in older men and women with advanced CKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

The Association Between Self-reported Shift Work and Change in Kidney Function in Women and Men in a Multiethnic Population: The HELIUS Study.

Journal of occupational and environmental medicine·2026
Same author

The Evaluation of Transformer Models for the Detection of Adverse Drug Events: A Benchmark Study Using Dutch Free-Text Documents of Hospitalized Patients.

Drug safety·2026

Related Experiment Video

Updated: Mar 5, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Relative risk versus absolute risk: one cannot be interpreted without the other.

Marlies Noordzij1, Merel van Diepen2, Fergus C Caskey3

  • 1ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|March 25, 2017
PubMed
Summary

Relative risk measures, often used in treatment studies, can obscure underlying absolute risks, leading to overestimations. Reporting both relative and absolute risks with confidence intervals offers a clearer understanding of treatment effects and clinical relevance.

Keywords:
absolute risk differenceepidemiologynumber needed to treatrelative riskrisk reduction

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

974

Related Experiment Videos

Last Updated: Mar 5, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

974

Area of Science:

  • Medical Statistics
  • Clinical Epidemiology
  • Health Research

Background:

  • Relative risk (RR) and absolute risk (AR) are crucial measures for presenting health outcomes.
  • Relative risk is frequently employed in clinical studies to summarize treatment effects.
  • However, RR can conceal underlying AR, potentially leading to misinterpretation of treatment efficacy.

Purpose of the Study:

  • To elucidate the concepts and implications of relative risk and absolute risk measures.
  • To highlight the importance of reporting both RR and AR in scientific literature.
  • To guide researchers in presenting risk data effectively for clinical decision-making.

Main Methods:

  • Conceptual explanation of relative risk and absolute risk.
  • Illustrative examples from nephrology research literature.
  • Analysis of how risk presentation impacts interpretation of clinical relevance.

Main Results:

  • Relative risk, while concise, can obscure absolute risk, leading to overestimation of treatment effects.
  • Absolute risk provides a more accurate representation of the actual situation and patient-relevant information.
  • Nephrology literature examples demonstrate the difficulty in judging clinical relevance without underlying absolute risks.

Conclusions:

  • Reporting relative risk alone can be misleading.
  • Absolute risk measures offer essential context for understanding the true impact of interventions.
  • Comprehensive risk reporting, including both relative and absolute risks with confidence intervals, is recommended for complete effect assessment.